Literature DB >> 10570269

Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.

X Y Mo1, P Cascio, K Lemerise, A L Goldberg, K Rock.   

Abstract

Most of the MHC class I peptides presented to the immune system are generated during the course of protein breakdown by the proteasome. However, the precise role of the proteasome, e.g., whether this particle or some other protease generates the carboxyl (C) and amino (N) termini of the presented 8- to 10-residue peptides, is not clear. Here, we show that presentation on Db of ASNENMETM, a peptide from influenza nucleoprotein, and on Kb of FAPGNYPAL, a peptide from Sendai virus nucleoprotein, was blocked by the proteasome inhibitor, lactacystin. Using plasmid minigene constructs encoding oligopeptides of various lengths, we found that presentation of ASNENMETM from C-terminally extended peptides that contain this antigenic peptide plus three or five additional amino acids and presentation of FAPGNYPAL from a peptide containing FAPGNYPAL plus one additional C-terminal residue required the proteasome. In contrast, the proteasome inhibitor did not reduce presentation of cytosolically expressed ASNENMETM or FAPGNYPAL or N-terminally extended versions of these peptides, suggesting involvement of aminopeptidase(s) in trimming these N-extended variants. Accordingly, when the N termini of these 3N-extended peptides were blocked by acetylation, they were resistant to hydrolysis by cellular aminopeptidases and pure leucine aminopeptidase. Moreover, if introduced into the cytosol, Ag presentation of these peptides occurred to a much lesser extent than from their nonacetylated counterparts. Thus, the proteasome is essential for the generation of ASNENMETM and FAPGNYPAL peptides from the full-length nucleoproteins. Although it generates the C termini of these presented peptides, distinct aminopeptidase(s) can trim the N termini of these presented peptides to their proper size.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1999        PMID: 10570269

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide.

Authors:  P Cascio; C Hilton; A F Kisselev; K L Rock; A L Goldberg
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides.

Authors:  Diego J Farfán-Arribas; Lawrence J Stern; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

3.  The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.

Authors:  Elena Milner; Lilach Gutter-Kapon; Michal Bassani-Strenberg; Eilon Barnea; Ilan Beer; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2013-03-28       Impact factor: 5.911

4.  Peptidomic analyses of mouse astrocytic cell lines and rat primary cultured astrocytes.

Authors:  Ping Yin; Ann M Knolhoff; Harry J Rosenberg; Larry J Millet; Martha U Gillette; Jonathan V Sweedler
Journal:  J Proteome Res       Date:  2012-07-16       Impact factor: 4.466

5.  Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Alla Berezovskaya; Andrew P Murray; Sascha Ansén; Seiji Kojima; Lee M Nadler
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

6.  Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.

Authors:  Michael D Robek; Mayra L Garcia; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Hepatitis C virus mutation affects proteasomal epitope processing.

Authors:  Ulrike Seifert; Heike Liermann; Vito Racanelli; Anne Halenius; Manfred Wiese; Heiner Wedemeyer; Thomas Ruppert; Kay Rispeter; Peter Henklein; Alice Sijts; Hartmut Hengel; Peter-M Kloetzel; Barbara Rehermann
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  NetCTLpan: pan-specific MHC class I pathway epitope predictions.

Authors:  Thomas Stranzl; Mette Voldby Larsen; Claus Lundegaard; Morten Nielsen
Journal:  Immunogenetics       Date:  2010-04-09       Impact factor: 2.846

Review 9.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

10.  Measurement of protein tyrosine phosphatase activity in single cells by capillary electrophoresis.

Authors:  Ryan M Phillips; Eric Bair; David S Lawrence; Christopher E Sims; Nancy L Allbritton
Journal:  Anal Chem       Date:  2013-05-30       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.